A Phase 3 interventional study of Inclisiran and Ezetimibe in Hypercholesterolemia, sponsored by Novartis Pharmaceuticals. Completed at 42 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing inclisiran in Hypercholesterolemia — 6 open to participants now, 10 under way, 5 of them phase 3. inclisiran · Hypercholesterolemia.
Among the 24 studies testing inclisiran in Hypercholesterolemia, this one is the 13th largest by enrollment, is one of 4 that started in 2023, is one of 13 in phase 3, and was the 14th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →6 of the 24 studies testing inclisiran in Hypercholesterolemia are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–75
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
Duke University · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in Argentina, Brazil
Ages 18–100
By country, each count listing its studies:
inclisiran: first FDA approval 2021 (LEQVIO), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 350 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 375 across the 24 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 24 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
36 studies in Hypercholesterolemia by Novartis: 6 open now, 10 under way, 5 of them phase 3. Of 26 finished, 10 (38%) have results posted.
Among the 36 studies in Hypercholesterolemia by Novartis, this one is the 15th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2023, is one of 17 in phase 3, and was the 22nd registered.
Novartis’s Hypercholesterolemia studies by the year they started, since 2002.
5 of the studies testing inclisiran in Hypercholesterolemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06501443Novartis PharmaceuticalsLATAM LOWERS LDL-C | 2026-11-27 |
| NCT06249165Duke UniversityVictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease | 2026-12-31 |
| NCT07610278Novartis PharmaceuticalsA Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia | 2027-04-28 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 5 to your calendar (.ics) → With an account.
Among the 24 studies testing inclisiran in Hypercholesterolemia, from their registry updates:
Among Novartis’s 36 in Hypercholesterolemia:
This tab as a report to print or save as PDF → With an account.
CKJX839D12304 was a research study to determine if the study treatment, called inclisiran, in comparison to placebo and ezetimibe effectively reduces Low-Density Lipoprotein Cholesterol (LDL-C) as measured by percentage change from baseline to Day 150. This study was conducted in eligible participants with primary hypercholesterolemia not receiving any lipid-lowering therapy (LLT), with a 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk of less than 7.5%.
This study was a randomized, double-blind, placebo- and active comparator-controlled, multicenter study in 350 adult participants with primary hypercholesterolemia not receiving any LLT with a 10-year ASCVD risk score of less than 7.5%. This study evaluated the efficacy and safety of inclisiran sodium 300 mg, administered as a monotherapy in comparison to ezetimibe and placebo.
The study consisted of:
The overall study duration was approximately 190 days.
Inclusion Criteria at screening:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Inclisiran s.c and Placebo p.o
Drug: Inclisiran · Drug: Matching Placebo for Ezetimibe
Placebo s.c. and Ezetimibe p.o.
Drug: Ezetimibe · Drug: Matching Placebo for Inclisiran
Placebo s.c. and Placebo p.o.
Drug: Matching Placebo for Inclisiran · Drug: Matching Placebo for Ezetimibe
284 mg (equivalent to 300 mg inclisiran sodium) subcutaneous injection given on Day 1 and Day 90
Also known as: KJX839
10 mg over-encapsulated tablet taken once a day from Day 1 through Day 149
Also known as: Sandoz ezetimibe
0mg placebo injection solution for subcutaneous injection on Day 1 and Day 90
Also known as: Placebo s.c.
0mg over-encapsulated placebo tablet taken once a day from Day 1 through Day 149
Also known as: Placebo p.o.
Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 150
Percentage change in LDL-C from Baseline (day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.
Time frame: Baseline, Day 150
Absolute Change in LDL-C From Baseline to Day 150
Absolute change in LDL-C from Baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.
Time frame: Baseline, Day 150
Percentage Change in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) From Baseline to Day 150
Percentage change in PCSK9 from Baseline (Day 1) to Day 150 , Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.
Time frame: Baseline, Day 150
Percentage Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Day 150
Percentage change in non-HDL-C from Baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.
Time frame: Baseline, Day 150
Percentage Change in Total Cholesterol (TC)/HDL-C Ratio From Baseline to Day 150
Percentage change in total cholesterol/HDL-C ratio from Baseline (Day1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strate
Time frame: Baseline, Day 150
Percentage Change in Apolipoprotein B (Apo B) From Baseline to Day 150
Percentage change in Apo B from Baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.
Time frame: Baseline, Day 150
Percentage Change in Apo B/Apo A-1 Ratio From Baseline to Day 150
Percentage change in Apo B/Apo A-1 ratio from baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.
Time frame: Baseline, Day 150
Change in Lipoprotein (a) [Lp(a)] From Baseline to Day 150
Day 150 / Baseline ratio in Lp(a) in Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.
Time frame: Baseline, Day 150
Incidence of Treatment Emergent Adverse Events (TEAE) and Serious Adverse Events (SAE)
Incidence of TEAEs (regardless of seriousness) and SAEs by treatment group, including changes in laboratory results qualifying and reported as AEs.
Time frame: From first dose of study treatment on Day 1 up to Day 180
Participants were enrolled at 42 investigative sites in 5 countries
| Milestone | Inclisiran | Ezetimibe | Placebo |
|---|---|---|---|
| Started | 174 | 89 | 87 |
| Completed | 164 | 86 | 84 |
| Not completed | 10 | 3 | 3 |
| Withdrew: Subject decision | 5 | 2 | 1 |
| Withdrew: Lost to follow-up | 4 | 1 | 2 |
| Withdrew: Adverse event | 1 | 0 | 0 |
Percentage change in LDL-C from Baseline (day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.
| Percentage change from baseline | Inclisiran | Ezetimibe | Placebo |
|---|---|---|---|
| LS Mean (Treatment Policy estimand) | -46.54 (-50.20 to -42.88) | -11.17 (-15.34 to -7.00) | 1.37 (-3.07 to 5.80) |
| LS Mean (Monotherapy estimand) | -49.37 (-52.76 to -45.97) | -11.92 (-15.87 to -7.98) | -1.53 (-2.97 to 6.03) |
Absolute change in LDL-C from Baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.
| mg/dL | Inclisiran | Ezetimibe | Placebo |
|---|---|---|---|
| LS Mean (Treatment Policy estimand) | -64.86 (-69.27 to -60.46) | -17.55 (-22.53 to -12.57) | -1.29 (-6.40 to 3.82) |
| LS Mean (Monotherapy estimand) | -68.57 (-72.59 to -64.56) | -18.52 (-23.16 to -13.89) | -1.07 (-6.32 to 4.19) |
Percentage change in PCSK9 from Baseline (Day 1) to Day 150 , Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.
| Percentage change from baseline | Inclisiran | Ezetimibe | Placebo |
|---|---|---|---|
| LS Mean (Treatment Policy estimand) | -67.12 (-73.21 to -61.03) | 6.04 (-0.10 to 12.18) | 7.82 (0.35 to 15.29) |
| LS Mean (Monotherapy estimand) | -71.31 (-76.73 to -65.89) | 5.56 (-0.67 to 11.79) | 8.16 (0.59 to 15.74) |
Percentage change in non-HDL-C from Baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.
| Percentage change from baseline | Inclisiran | Ezetimibe | Placebo |
|---|---|---|---|
| LS Mean (Treatment Policy estimand) | -40.45 (-43.50 to -37.40) | -9.97 (-13.34 to -6.61) | 1.88 (-2.75 to 6.50) |
| LS Mean (Monotherapy estimand) | -42.82 (-45.62 to -40.02) | -10.84 (-13.84 to -7.84) | 2.04 (-2.63 to 6.71) |
Percentage change in total cholesterol/HDL-C ratio from Baseline (Day1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strate
| Percentage change from baseline | Inclisiran | Ezetimibe | Placebo |
|---|---|---|---|
| LS Mean (Treatment Policy estimand) | -31.54 (-35.43 to -27.65) | -6.70 (-10.61 to -2.78) | 2.31 (-4.05 to 8.68) |
| LS Mean (Monotherapy estimand) | -33.56 (-37.32 to -29.79) | -6.98 (-10.99 to -2.97) | 2.51 (-3.90 to 8.91) |
Percentage change in Apo B from Baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.
| Percentage change from baseline | Inclisiran | Ezetimibe | Placebo |
|---|---|---|---|
| LS Mean (Treatment Policy estimand) | -37.39 (-40.25 to -34.54) | -8.41 (-11.71 to -5.12) | -0.73 (-4.18 to 2.72) |
| LS Mean (Monotherapy estimand) | -39.36 (-42.00 to -36.72) | -9.20 (-12.13 to -6.28) | -0.58 (-4.07 to 2.90) |
Percentage change in Apo B/Apo A-1 ratio from baseline (Day 1) to Day 150, Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.
| Percentage change from baseline | Inclisiran | Ezetimibe | Placebo |
|---|---|---|---|
| LS Mean (Treatment Policy estimand) | -37.79 (-43.03 to -32.55) | -7.55 (-11.74 to -3.36) | -2.65 (-5.69 to 0.39) |
| LS Mean (Monotherapy estimand) | -40.03 (-45.25 to -34.82) | -7.69 (-12.00 to -3.37) | -2.65 (-5.81 to 0.50) |
Day 150 / Baseline ratio in Lp(a) in Inclisiran arm versus Ezetimibe and placebo. There were two estimands of interest in comparing efficacy of inclisiran as monotherapy against that of placebo or ezetimibe that differ on the treatment of interest used for each and the management of intercurrent events as follows: * Monotherapy Estimand: Inclisiran as monotherapy compared to the use of comparator. This estimand uses a hypothetical strategy where participants who permanently discontinued treatment, died or used other LLTs were handled in a hypothetical scenario of what would have happened if the intercurrent event did not happen. * Treatment-policy Estimand: Inclisiran as monotherapy compared to the use of comparator with or without other lipid lowering therapies (LLTs) added. This estimand ignored the use of other LLTs and treatment discontinuation. Deaths (if any) were handled as an unfavorable outcome using a composite variable strategy.
| Ratio from baseline | Inclisiran | Ezetimibe | Placebo |
|---|---|---|---|
| LS Mean (Treatment Policy estimand) | 0.690 (0.611 to 0.780) | 0.911 (0.830 to 1.000) | 0.923 (0.803 to 1.060) |
| LS Mean (Monotherapy estimand) | 0.687 (0.612 to 0.722) | 0.912 (0.836 to 0.95) | 0.922 (0.800 to 1.062) |
Incidence of TEAEs (regardless of seriousness) and SAEs by treatment group, including changes in laboratory results qualifying and reported as AEs.
| Participants | Inclisiran | Ezetimibe | Placebo |
|---|---|---|---|
| AEs | 54 | 27 | 25 |
| AEs related to s.c. treatment (Inclisiran or s.c. matching placebo) | 11 | 4 | 0 |
| AEs related to p.o. treatment (ezetimibe or p.o. matching placebo) | 3 | 2 | 2 |
| SAEs | 1 | 0 | 0 |
| SAEs related to s.c. treatment (Inclisiran or s.c. matching placebo) | 0 | 0 | 0 |
| SAEs related to p.o. treatment (ezetimibe or p.o. matching placebo) | 0 | 0 | 0 |
| Fatal SAEs | 0 | 0 | 0 |
| AEs leading to treatment discontinuation of inclisiran or s.c. matching placebo | 3 | 0 | 0 |
| AEs leading to treatment discontinuation of ezetimibe or p.o. matching placebo | 4 | 0 | 0 |
Collected over From first dose of study treatment on Day 1 up to Day 180. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Inclisiran | 0/174 (0%) | 1/174 (0.6%) | 19/174 (10.9%) |
| Ezetimibe | 0/89 (0%) | 0/89 (0%) | 18/89 (20.2%) |
| Placebo | 0/87 (0%) | 0/87 (0%) | 13/87 (14.9%) |
| Total | 0/350 (0%) | 1/350 (0.3%) | 50/350 (14.3%) |
| Event | Inclisiran | Ezetimibe | Placebo | Total |
|---|---|---|---|---|
| Femur fractureInjury, poisoning and procedural complications | 1/174 | 0/89 | 0/87 | 1/350 |
| Event | Inclisiran | Ezetimibe | Placebo | Total |
|---|---|---|---|---|
| COVID-19Infections and infestations | 1/174 | 2/89 | 3/87 | 6/350 |
| NasopharyngitisInfections and infestations | 6/174 | 3/89 | 3/87 | 12/350 |
| HeadacheNervous system disorders | 6/174 | 0/89 | 0/87 | 6/350 |
| DiarrhoeaGastrointestinal disorders | 2/174 | 1/89 | 2/87 | 5/350 |
| Urinary tract infectionInfections and infestations | 3/174 | 2/89 | 2/87 | 7/350 |
| HypertensionVascular disorders | 1/174 | 1/89 | 2/87 | 4/350 |
| VomitingGastrointestinal disorders | 2/174 | 2/89 | 0/87 | 4/350 |
| GastroenteritisInfections and infestations | 2/174 | 2/89 | 0/87 | 4/350 |
| Upper respiratory tract infectionInfections and infestations | 2/174 | 2/89 | 1/87 | 5/350 |
| FallInjury, poisoning and procedural complications | 0/174 | 2/89 | 1/87 | 3/350 |
| Age, Categorical(Participants) | Inclisiran | Ezetimibe | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 168 | 86 | 83 | 337 |
| >=65 years | 6 | 3 | 4 | 13 |
| Age, Continuous(years) | Inclisiran | Ezetimibe | Placebo | Total |
|---|---|---|---|---|
| Mean | 45.7 ± 11.74 | 46.3 ± 10.90 | 46.7 ± 11.55 | 46.1 ± 11.46 |
| Sex: Female, Male(Participants) | Inclisiran | Ezetimibe | Placebo | Total |
|---|---|---|---|---|
| Female | 104 | 56 | 59 | 219 |
| Male | 70 | 33 | 28 | 131 |
| Race (NIH/OMB)(Participants) | Inclisiran | Ezetimibe | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 10 | 10 | 9 | 29 |
| Asian | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 20 | 7 | 10 | 37 |
| White | 140 | 71 | 67 | 278 |
| More than one race | 4 | 0 | 1 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Baseline Low-Density Lipoprotein Cholesterol (LDL-C)(mg/dL) | Inclisiran | Ezetimibe | Placebo | Total |
|---|---|---|---|---|
| Mean | 135.8 ± 27.01 | 134.4 ± 25.82 | 135.4 ± 28.69 | 135.4 ± 27.07 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Mar 2023 to primary completion in Jun 2024, 15 months.
Results were first posted in Aug 2025, 1 year 1 month after primary completion.
Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 15 months is below that.
Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inclisiran